FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer
Open Access
- 8 June 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Abstract
FOXA family proteins act as pioneer factors by remodeling compact chromatin structures. FOXA1 is crucial for the chromatin binding of the androgen receptor (AR) in both normal prostate epithelial cells and the luminal subtype of prostate cancer (PCa). Recent studies have highlighted the emergence of FOXA2 as an adaptive response to AR signaling inhibition treatments. However, the role of the FOXA1 to FOXA2 transition in regulating cancer lineage plasticity remains unclear. Our study demonstrates that FOXA2 binds to distinct classes of developmental enhancers in multiple AR-independent PCa subtypes, with its binding depending on LSD1. Moreover, we reveal that FOXA2 collaborates with JUN at chromatin and promotes transcriptional reprogramming of AP-1 in lineage-plastic cancer cells, thereby facilitating cell state transitions to multiple lineages. Overall, our findings underscore the pivotal role of FOXA2 as a pan-plasticity driver that rewires AP-1 to induce the differential transcriptional reprogramming necessary for cancer cell lineage plasticity.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA211350, U54CA156734, U54 CA156734)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-19-1-0361, W81XWH-21-1-0267, W81XWH-19-1-0777)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- Movember Foundation (MNBCF-17-012, MNBCF-17-012)
- Department of Health, State Government of Victoria (MCRF15023)
- Department of Health, State Government of Victoria (MCRF18017)
- Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (142246, 159567)
This publication has 61 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Pioneer factors in hormone-dependent cancersNature Reviews Cancer, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Siah2-Dependent Concerted Activity of HIF and FoxA2 Regulates Formation of Neuroendocrine Phenotype and Neuroendocrine Prostate TumorsCancer Cell, 2010
- Nuclear Mobility and Mitotic Chromosome Binding: Similarities between Pioneer Transcription Factor FoxA and Linker Histone H1Cold Spring Harbor Symposia on Quantitative Biology, 2010
- Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1Nature Biotechnology, 2008
- FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific TranscriptionCell, 2008
- Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independenceThe Prostate, 2008
- Regulation of LSD1 Histone Demethylase Activity by Its Associated FactorsMolecular Cell, 2005
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004